Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2020 | Editorial

¹⁸F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

Authors: Giorgio Treglia, Luca Ceriani

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2020

Excerpt

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative diseases occurring after solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT). Epstein-Barr virus (EBV) serology mismatch among recipient and donor, type of transplanted organ, and intensity and type of immunosuppression are considered as established risk factors for developing PTLD. The risk is also higher among children compared with adults [1]. …

DeStefano CB, Desai SH, Shenoy AG, Catlett JP. Management of post-transplant lymphoproliferative disorders. Br J Haematol. 2018;182(3):330–43.CrossRef

Aguilera N, Gru AA. Reexamining post-transplant lymphoproliferative disorders: newly recognized and enigmatic types. Semin Diagn Pathol. 2018;35(4):236–46.CrossRef

NCCN Clinical practice guidelines in oncology. B-Cell Lymphomas Version 4.2019. Available at https://www.nccn.org/professionals/physician_gls/default.aspx.

Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;23:e13652. https://doi.org/10.1111/ctr.13652.CrossRef

Montes de Jesus FM, Kwee TC, Kahle XU, Nijland M, van Meerten T, Huls G, et al. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04481-7.

Dierickx D, Tousseyn T, Requilé A, Verscuren R, Sagaert X, Morscio J, et al. The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder. Haematologica. 2013;98(5):771–5.CrossRef

Noraini AR, Gay E, Ferrara C, Ravelli E, Mancini V, Morra E, et al. PET-CT as an effective imaging modality in the staging and follow-up of post-transplant lymphoproliferative disorder following solid organ transplantation. Singap Med J. 2009;50(12):1189–95.

Panagiotidis E, Quigley AM, Pencharz D, Ardeshna K, Syed R, Sajjan R, et al. (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis of post-transplant lymphoproliferative disorder. Leuk Lymphoma. 2014;55(3):515–9.CrossRef

Montes de Jesus FM, Kwee TC, Nijland M, Kahle XU, Huls G, Dierckx RAJO, et al. Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;132:27–38.CrossRef

10.

Muller N, Kessler R, Caillard S, Epailly E, Hubelé F, Heimburger C, et al. (18)F-FDG PET/CT for the diagnosis of malignant and infectious complications after solid organ transplantation. Nucl Med Mol Imaging. 2017;51(1):58–68.CrossRef

11.

Van Keerberghen CA, Goffin K, Vergote V, Tousseyn T, Verhoef G, Laenen A, et al. Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder. Acta Oncol. 2019;58(7):1041–7.CrossRef

12.

Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, et al. End-of-treatment positron emission tomography after uniform first-line therapy of B-cell Posttransplant lymphoproliferative disorder identifies patients at low risk of relapse in the prospective German PTLD registry. Transplantation. 2018;102(5):868–75.CrossRef

Title: 18F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good
Authors: Giorgio Treglia
Luca Ceriani
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-019-04518-x

At a glance: The STEP trials

Springer Medicine

¹⁸F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2020

Isolated involvement of thyroid gland by IgG4-related disease revealed by 18F-FDG PET/CT

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia

Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies

Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer